KLRS Kalaris Therapeutics Inc
Healthcare$5.21+5.89%ClosedMarket Cap: $97.4M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.70
P/S
0.00
EV/EBITDA
-1.29
DCF Value
$6.25
FCF Yield
-53.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-72.8%
ROA
-40.2%
ROIC
-46.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-11.8M | $-10.9M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-10.8M | $-10.0M | $— | — |
| FY null | $0.00 | -Infinity% | $-46.2M | $-43.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-12.7M | $-11.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-12.3M | $-11.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-10.4M | $-10.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-19.5M | $-18.3M | $— | — |
| FY null | $0.00 | NaN% | $-55.3M | $-58.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-37.8M | $-38.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-4.2M | $-5.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.6M | $-3.4M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-3.5M | $-3.5M | $-0.70 | — |